MA-EDB
2.11.2021 13:02:12 CET | Business Wire | Press release
EDB , a leading contributor to PostgreSQL®, today announced the general availability of its BigAnimal™ offering, the first fully-managed PostgreSQL database in the cloud with compatibility for Oracle database technology. Built and backed by the world’s largest roster of PostgreSQL engineers, BigAnimal is for enterprises looking to deploy their most demanding databases into the cloud.
“BigAnimal was built in direct response to what our customers told us was missing from existing cloud Postgres offerings,” said EDB president and CEO, Ed Boyajian. “These improvements aren’t incremental - they’re transformational. We’ve made no compromises. This means you get fanatical attention from the biggest team in Postgres, native compatibility with Oracle database technology, and extreme high availability. And we run it all inside your cloud account.”
Accelerate Business with the Best Cloud PostgreSQL
Customers who are building serious cloud applications are realizing that they can’t get what they need from the basic PostgreSQL offerings available today. Without the transparency, control, and performance tuning required for their most demanding workloads, they are held back from moving fully into the cloud. BigAnimal responds to these needs by giving organizations granular control over the database within their own accounts and all the enterprise PostgreSQL capabilities EDB has been developing over the past 15 years - while being fully managed by EDB.
Specifically, with BigAnimal, enterprises will experience the following benefits:
- Partner with PostgreSQL builders . For over a decade, PostgreSQL users have counted on EDB for their on-premises deployments. Now with BigAnimal, users can also rely on unequaled support from EDB’s world-class PostgreSQL experts.
- Migrate applications on Oracle databases to PostgreSQL on Azure with little to no changes needed. With BigAnimal, customers can reduce costs, time, and risks when migrating workloads from legacy Oracle databases to cloud environments. BigAnimal’s deep compatibility with Oracle database technology and comprehensive migration tools address a critical need for enterprises who want to move quickly without leaving behind all their legacy database investments in code, skill sets, and resources.
- Increase transparency and control of their cloud PostgreSQL . BigAnimal runs in a customer’s cloud account, allowing them to closely manage, secure, and optimize their PostgreSQL along with their other infrastructure according to their business needs and spend commitments. BigAnimal also gives users an unprecedented level of control over their PostgreSQL with superuser access to precisely tweak database internals.
- Minimize complexity with the same PostgreSQL everywhere. EDB Postgres users can expect a uniform database experience, from EDB Postgres on premises to BigAnimal on Azure. This includes the ability to use their existing PostgreSQL skill sets, incorporate the database into their DevOps pipelines, and leverage EDB Postgres Advanced enterprise capabilities, such as enhanced security, performance management, and compatibility with Oracle database technology. With support for license portability, EDB also allows customers to easily deploy PostgreSQL whenever, wherever their business requires.
According to Carl Olofson, research vice president, Data Management Software, IDC: “In 2021, we saw a significant rise in cloud infrastructure spend and expect it to soon surpass non-cloud infrastructure. With this growing reliance on cloud platforms, many companies don’t have the in-house skills to deploy, manage, and optimize their databases. Considering EDB’s long track record of building and supporting Postgres, companies have a strong option for transitioning smoothly and optimizing their cloud database operations.”
For more information about EDB and BigAnimal and to sign up for a trial, please visit www.biganimal.com .
EnterpriseDB, EDB and Postgres Enterprise Manager are registered trademarks of EnterpriseDB Corporation. EDB Postgres and BigAnimal are trademarks of EnterpriseDB Corporation.
Postgres, PostgreSQL, and the Slonik Logo are trademarks or registered trademarks of the PostgreSQL Community Association of Canada, and used with their permission.
About EDB
PostgreSQL is increasingly the database of choice for organizations looking to boost innovation and accelerate business. EDB’s enterprise-class software extends PostgreSQL, helping our customers get the most out of it both on premises and in the cloud. And our 24x7 global support, professional services, and training help our customers control risk, manage costs, and scale efficiently. With 16 offices worldwide, EDB serves over 5,000 customers, including leading financial services, government, media and communications, and information technology organizations. To learn about PostgreSQL for people, teams, and enterprises, visit EDBpostgres.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005218/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom